Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

298.24 +1.39 (+0.47%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies. 
Via Benzinga
Analyst Expectations For Amgen's Future
Via Benzinga
This Is What Whales Are Betting On Amgen
Via Benzinga
Unpacking the Latest Options Trading Trends in Amgen
Via Benzinga
Earnings Scheduled For February 4, 2025
Via Benzinga
Markets React To Softening Trade Tariff Policy
Monday’s trading session resulted in slight negative closes across major indexes, but there’s good news here: whereas the Dow finished the trading day -122 points, it was -400 a half hour before this... 
Via Talk Markets
Topics Stocks Stocks / Equities
The Dogs Of The Dow 2025
The Dogs of the Dow is an investing strategy well-known to retail and institutional investors. 
Via Talk Markets
Topics Stocks Stocks / Equities
Friday's pre-market session: top gainers and losers in the S&P500 index
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
Via The Motley Fool
Topics Stocks
Peering Into Amgen's Recent Short Interest
Via Benzinga
Analyst Expectations For Amgen's Future
Via Benzinga
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
The Danish drug giant reported a 22% weight loss over 36 weeks. 
Via Investor's Business Daily
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals. 
Via Benzinga
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
Via The Motley Fool
Topics Stocks
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation
Amgen's Lumakras treatment, combined with Vectibix, is FDA-approved for KRAS G12C-mutated colorectal cancer. 
Via Benzinga
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Via The Motley Fool
What Lies Ahead In 2025? Slower Growth, More Volatility
As we move through 2025, the global economy and financial markets are facing a critical juncture. 
Via Talk Markets
Topics Economy Stocks / Equities
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
3 High-Yield Dividend Stocks to Buy in 2025
Via The Motley Fool
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
UK Greenlights Amgen's Drug For Aggressive Lung Cancer In Pretreated Patients
Amgen's Imdylltra gets MHRA nod for ES-SCLC after two prior therapies, offering new hope for aggressive cancer with limited treatment options. 
Via Benzinga
Prediction: These 3 Healthcare Stocks Will Soar in 2025
Via The Motley Fool
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Dissecting Our Discipline
All portfolio managers practice a stock-picking discipline in which they make choices. 
Via Talk Markets
Topics Stocks / Equities
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
In the Dow Jones Industrial Average, 28 of the 30 components pay dividends. With changes to the components in 2024, dividend yield is smaller overall. 
Via Benzinga
Topics Stocks
3 Worst Performing Dow Jones Stocks In 2024
The Dow Jones Industrial Average will finish 2024 with a positive return. The index has climbed about 24% this year. 
Via Talk Markets
Topics Stocks Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS